Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

New England Journal of Medicine

Volumn 354, Issue 24, 2006, Pages 2542-2551

  Kantarjian, Hagop ^a   Giles, Francis ^a   Wunderle, Lydia ^b   Bhalla, Kapil ^c   O'Brien, Susan ^a   Wassmann, Barbara ^b   Tanaka, Chiaki ^d   Manley, Paul ^d   Rae, Patricia ^d   Mietlowski, William ^d   Bochinski, Kathy ^d   Hochhaus, Andreas ^f   Griffin, James D ^g   Hoelzer, Dieter ^b   Albitar, Maher ^e   Dugan, Margaret ^d   Cortes, Jorge ^a   Alland, Leila ^d   Ottmann, Oliver G ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^f MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 33745086350     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa055104     Document Type: Article

References (24)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.
3. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104:11a. abstract.
4. Towartari M, Yanada M, Usui N, et al. Combination of intensive chemotherapy with imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507-12.
5. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
6. Ottmann OG, Wassmann B, Goekbuget N, et al. A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia. Blood 2003;102:226a. abstract.
7. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407.
8. Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005;104:1230-6.
9. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005;11:4941-7.
10. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-4. [Erratum, Cancer Cell 2005;7:399.]
11. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
12. Manley P, von Bubnoff N, Duyster J, et al. AMN107: inhibitory profile against wild-type and mutant forms of the BCR-ABL tyrosine kinase. Presented at the 96th annual meeting of the American Association for Cancer Research, Anaheim, Calif., April 16-20, 2005. abstract.
13. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19.
14. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6.
15. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 1987;83:445-54.
16. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. [Erratum, N Engl J Med 2002;346:1923.]
17. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-800.
18. O'Quigley J, Shen LZ, Gamst A. Two-sample continual reassessment method. J Biopharm Stat 1999;9:17-44.
19. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
20. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
21. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-9.
22. Bosma P, Chowdhury J, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
23. Deininger M, O'Brien S, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:4255-6.
24. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.